Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) postdocetaxel. Preclinical studies have demonstrated impressive affinity to the AR compared to the first-generation AR inhibitors. The landmark Phase III AFFIRM trial demonstrated improved overall survival benefit compared to placebo in addition to improvement in all tested parameters. Enzalutamide is currently being studied in several trials prechemotherapy and in earlier settings of prostate cancer. This review will discuss the mechanism of action of enzalutamide, its pharmacokinetics, the preclinical and clinical trials that led to its approval, the ongoing clinical trials, its safety and efficacy, as well as patterns of resistance, and discusses its place in therapy within the context of several recently approved agents for mCRPC.
Written by:
El-Amm J, Patel N, Freeman A, Aragon-Ching JB. Are you the author?
Department of Medicine, Division of Hematology/Oncology, George Washington University Medical Center, Washington, DC, USA.
Reference: Clin Med Insights Oncol. 2013 Aug 21;7:235-245.
doi: 10.4137/CMO.S11670
PubMed Abstract
PMID: 24179414
Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com
UroToday.com mCRPC Treatment Section
